A Look at FDA's Pandemic Inspections Q&A Guidance

Описание: The FDA Group’s CEO, Nick Capman, breaks down the FDA’s Q&A guidance on drug and biologic inspections during the pandemic, pointing out the important takeaways manufacturers should consider and prepare for.

Read our blog post for a written breakdown of the key takeaways we explore here: https://bit.ly/3nUbHbV

We've also written on FDA's more recent guidance outlining its expectations for resuming normal manufacturing operations during the pandemic. Read that post here: https://bit.ly/3iZ6A6m

Need expert quality system remediation assistance? Learn more about our quality system remediation services: https://bit.ly/3jUMnA5

Get in touch with us: https://bit.ly/3lzMTns
Follow The FDA Group on LinkedIn: https://bit.ly/312F020

About The FDA Group:
The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations.

We help thousands of firms find the resources they need, when and where they need them, through the optimal workforce model. Our resources are located in several dozen countries and have expertise throughout the life sciences.